Fisher Andrew's Form 4 filing
Verona Pharma plc (VRNA) · filed Jun 18, 2025
- Accession no.
- 0001104659-25-060652
- Filed
- Jun 18, 2025
- Trade date
- Jun 16, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $922.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fisher AndrewCIK 0002014301 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | Ordinary Shares | MOption exerciseAcquired | +80,000 | $2.01 | +$160,800 | 439,999 | Direct | |
| Jun 16, 2025 | Ordinary Shares | SSaleDisposed | −80,000 | $11.53 | −$922,400 | 359,999 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | Ordinary Shares | MOption exerciseDisposed | −80,000 | $0.00 | $0 | 2,240,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.